Table 2.
One-way ANOVA (p) | Post hoc 1–2 (p) | Post hoc 1–3 (p) | Post hoc 2–3 (p) | 95% CI 1–2 | 95% CI 1–3 | 95% CI 2–3 | |
---|---|---|---|---|---|---|---|
Baseline parameters | |||||||
IL 6 d1 | 0.286 | 0.999 | 0.374 | 0.304 | − 254–263 | − 458–129 | − 443–105 |
CRP d1 | 0.805 | 0.861 | 0.813 | 0.985 | − 8.08–5.19 | − 9.47–5.62 | − 7.52–6.54 |
Creatinine d1 | < 0.001 | 0.702 | < 0.001 | < 0.001 | − 0.7–0.4 | − 1.7 to − 0.5 | − 1.5 to − 0.3 |
Urea d1 | 0.001 | 0.260 | 0.001 | 0.021 | − 35–7 | − 64 to − 16 | − 48 to − 3 |
CLCR d1 | < 0.001 | 0.002 | < 0.001 | 0.007 | 17–88 | 61–138 | 11–83 |
RRT d1 | 0.066 | 0.832 | 0.066 | 0.146 | − 0.3–0.2 | − 0.6–0.02 | − 0.5–0.06 |
Bilirubin d1 | 0.499 | 0.947 | 0.677 | 0.475 | − 1.5–1.9 | − 2.6–1.2 | − 2.6–0.9 |
ALT d1 | 0.723 | 0.781 | 0.754 | 0.988 | − 174–306 | − 196–361 | − 249–281 |
AST d1 | 0.728 | 0.938 | 0.900 | 0.706 | − 308–230 | − 250–361 | − 191–379 |
GGT d1 | 0.283 | 0.931 | 0.482 | 0.261 | − 108–145 | − 213–75 | − 222–46 |
APACHE II d1 | 0.026 | 0.989 | 0.061 | 0.03 | − 5.0–5.6 | − 11.8–0.2 | − 11.7 to − 0.5 |
SOFA d1 | 0.133 | 0.123 | 0.338 | 0.703 | − 4.3–1.1 | − 5.7–0.5 | − 3.8–1.9 |
Age | 0.010 | 0.204 | 0.007 | 0.183 | − 17.1–2.8 | − 26.3 to − 3.6 | − 18.4–2.7 |
BMI | 0.845 | 1.00 | 0.874 | 1.00 | − 11.0–11.0 | − 10.0–15.1 | − 9.1–14.3 |
Sex | 0.78 | 0.82 | 0.806 | 0.994 | − 0.5–0.3 | − 0.6–0.3 | − 0.4–0.4 |
Delta parameters | |||||||
ΔIL-6 (d1–d3) | 0.236 | 0.959 | 0.255 | 0.319 | − 291–231 | − 494–100 | − 444–109 |
ΔCRP (d1–d3) | 0.015 | 0.033 | 0.026 | 0.903 | − 11.2 to − 0.4 | − 12.9 to − 0.67 | − 6.7–4.7 |
ΔCreatinine (d1–d5) | 0.253 | 0.900 | 0.236 | 0.37 | − 0.4–0.6 | − 0.2–1.1 | − 0.3–1.0 |
ΔUrea (d1–d5) | 0.327 | 0.79 | 0.657 | 0.298 | − 34–20 | − 21–45 | − 12–50 |
ΔCLCR (d1–d5) | 0.419 | 0.398 | 0.891 | 0.763 | − 22–73 | − 45–66 | − 67–37 |
ΔBilirubin (d1–d5) | 0.946 | 0.957 | 1.00 | 0.961 | − 1.3–1.7 | − 1.7–1.7 | − 1.7–1.4 |
ΔALT (d1–d5) | 0.526 | 0.632 | 0.553 | 0.978 | − 174–306 | − 196–361 | − 249–281 |
ΔAST (d1–d5) | 0.781 | 0.999 | 0.841 | 0.782 | − 242–232 | − 206–330 | − 175–310 |
ΔGGT (d1–d5) | 0.765 | 0.951 | 0.750 | 0.869 | − 190–244 | − 171–319 | − 175–268 |
ΔAPACHE II (d1–d5) | 0.227 | 0.358 | 0.231 | 0.887 | − 1.3–4.7 | − 1.0–5.6 | − 2.4–3.6 |
ΔSOFA (d1–d5) | 0.215 | 0.197 | 0.766 | 0.597 | − 1.7–10.3 | − 4.8–8.6 | − 10.3–1.7 |
Neurological disorder d5 | 0.43 | 0.473 | 0.518 | 0.997 | − 0.6–0.2 | − 0.6–0.2 | − 0.4–0.4 |
In-hospital mortality | 0.002 | 0.728 | 0.001 | 0.017 | − 0.2 – 0.4 | − 0.7 to − 0.06 | − 0.8 to − 0.2 |
Estimated mortality | 0.123 | 0.996 | 0.198 | 0.135 | − 0.1 – 0.1 | − 0.3–0.05 | − 0.3–0.03 |
ANOVA analysis of variance, CI confidence interval, IL-6 interleukin-6, CRP C-reactive protein, ALT serum alanine aminotransferase, AST serum aspartate aminotransferase, GGT glutamine glutamyl transferase, CLCR creatinine clearance, RRT renal replacement therapy, d day, BMI body mass index